NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
1.350
+0.040 (3.05%)
Oct 4, 2024, 4:00 PM EDT - Market closed

Company Description

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.

The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.

Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules.

It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

NextCure, Inc.
NextCure logo
Country United States
Founded 2015
IPO Date May 9, 2019
Industry Biotechnology
Sector Healthcare
Employees 82
CEO Michael Richman

Contact Details

Address:
9000 Virginia Manor Road, Suite 200
Beltsville, Maryland 20705
Phone 240 399 4900
Website nextcure.com

Stock Details

Ticker Symbol NXTC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001661059
CUSIP Number 65343E108
ISIN Number US65343E1082
Employer ID 47-5231247
SIC Code 2834

Key Executives

Name Position
Michael S. Richman MSBA Co-Founder, Chief Executive Officer, President and Director
Dr. Solomon Langermann Ph.D. Chief Scientific Officer
Dr. Lieping Chen M.D., Ph.D. Co-Founder and Chairman of Scientific Advisory Board
Steven P. Cobourn CPA Chief Financial Officer
Dr. Timothy Mayer Ph.D. Chief Operating Officer
Kevin G. Shaw Senior Vice President and General Counsel
Sourav Kundu Ph.D. Senior Vice President of Development and Manufacturing
Dr. Sebastien Maloveste Ph.D. Senior Vice President of Business Development
Dr. Udayan Guha M.D., Ph.D. Senior Vice President of Clinical and Translational Development

Latest SEC Filings

Date Type Title
Aug 1, 2024 10-Q Quarterly Report
Aug 1, 2024 8-K Current Report
Jun 27, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Jun 21, 2024 8-K Current Report
Jun 18, 2024 8-K Current Report
May 2, 2024 10-Q Quarterly Report
May 2, 2024 8-K Current Report
Apr 26, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 26, 2024 DEF 14A Other definitive proxy statements
Apr 16, 2024 PRE 14A Other preliminary proxy statements